DE60121145D1 - Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln - Google Patents
Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormittelnInfo
- Publication number
- DE60121145D1 DE60121145D1 DE60121145T DE60121145T DE60121145D1 DE 60121145 D1 DE60121145 D1 DE 60121145D1 DE 60121145 T DE60121145 T DE 60121145T DE 60121145 T DE60121145 T DE 60121145T DE 60121145 D1 DE60121145 D1 DE 60121145D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- tumors
- antitumum
- compounds together
- retinoid compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54214800A | 2000-04-04 | 2000-04-04 | |
| US542148 | 2000-04-04 | ||
| PCT/US2001/010410 WO2001074759A1 (en) | 2000-04-04 | 2001-04-02 | Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60121145D1 true DE60121145D1 (de) | 2006-08-10 |
| DE60121145T2 DE60121145T2 (de) | 2007-05-31 |
Family
ID=24162539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60121145T Expired - Lifetime DE60121145T2 (de) | 2000-04-04 | 2001-04-02 | Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6387950B2 (de) |
| EP (2) | EP1268405B1 (de) |
| JP (1) | JP2003534246A (de) |
| AT (1) | ATE331703T1 (de) |
| AU (1) | AU2001253045A1 (de) |
| CA (1) | CA2405136C (de) |
| DE (1) | DE60121145T2 (de) |
| ES (1) | ES2267754T3 (de) |
| TW (1) | TWI281911B (de) |
| WO (1) | WO2001074759A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6903121B1 (en) | 2000-08-17 | 2005-06-07 | Allergan, Inc. | Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| ATE413375T1 (de) * | 2000-10-02 | 2008-11-15 | Hoffmann La Roche | Retinoide zur behandlung von emphysem |
| EP1935869A1 (de) * | 2000-10-02 | 2008-06-25 | F. Hoffmann-La Roche Ag | Retinoide zur Behandlung von Emphysem |
| US6620963B1 (en) | 2002-09-19 | 2003-09-16 | Allergan, Inc. | TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY |
| WO2005093426A2 (en) * | 2004-03-26 | 2005-10-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara) |
| SI1937244T1 (sl) | 2005-09-30 | 2018-12-31 | Io Therapeutics, Llc | Zdravljenje raka s specifičnimi RXR agonisti |
| WO2012125749A2 (en) * | 2011-03-14 | 2012-09-20 | Io Therapeutics, Inc. | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| MX352727B (es) | 2011-12-13 | 2017-12-06 | Dartmouth College | Tratamiento de trastorno autoinmune al usar agonistas de rxr. |
| IL294449B1 (en) | 2015-03-31 | 2024-01-01 | Syros Pharmaceuticals Inc | Methods for stratifying patients for treatment with retinoic acid alpha receptor agonists |
| PL3368080T3 (pl) | 2015-10-31 | 2023-09-11 | Io Therapeutics, Inc. | Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy |
| EP4098257A1 (de) | 2015-11-25 | 2022-12-07 | IO Therapeutics, Inc. | Verwendung von cyp26-resistenten rar-alpha-selektiven agonisten in der behandlung von krebs |
| KR20230164204A (ko) | 2016-03-10 | 2023-12-01 | 아이오 테라퓨틱스, 인크. | Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료 |
| EP3426303B1 (de) | 2016-03-10 | 2022-06-15 | IO Therapeutics, Inc. | Behandlung von muskelerkrankungen mit kombinationen von rxr-agonisten und schilddrüsenhormonen |
| US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
| AU2017248187B2 (en) | 2016-04-08 | 2023-03-16 | Syros Pharmaceuticals, Inc. | Rara agonists for the treatment of AML and MDS |
| IL302133A (en) | 2017-07-13 | 2023-06-01 | Io Therapeutics Inc | A combination of a rexinoid and retinoid substance with immunomodulatory properties and immunomodulatory substances for cancer treatment |
| AU2018326617B2 (en) | 2017-08-31 | 2022-12-01 | Io Therapeutics, Inc. | Rar selective agonists in combination with immune modulators for cancer immunotherapy |
| CA3076373A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | Treatment of disease with esters of selective rxr agonists |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| US11896558B2 (en) | 2021-12-07 | 2024-02-13 | Io Therapeutics, Inc. | Use of an RXR agonist and taxanes in treating Her2+ cancers |
| CN114703227B (zh) * | 2022-01-27 | 2023-11-10 | 中国科学院生态环境研究中心 | 基于MCF-7细胞系构建的RARα效应物体外筛选方法 |
| US11976021B2 (en) | 2022-06-27 | 2024-05-07 | Io Therapeutics, Inc. | Synthesis of tetrahydronaphthalenols and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993011755A1 (en) * | 1991-12-18 | 1993-06-24 | The Salk Institute For Biological Studies | Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor |
| US5675024A (en) | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
| US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
-
2001
- 2001-03-30 TW TW090107695A patent/TWI281911B/zh not_active IP Right Cessation
- 2001-04-02 AU AU2001253045A patent/AU2001253045A1/en not_active Abandoned
- 2001-04-02 WO PCT/US2001/010410 patent/WO2001074759A1/en active IP Right Grant
- 2001-04-02 AT AT01926512T patent/ATE331703T1/de not_active IP Right Cessation
- 2001-04-02 CA CA002405136A patent/CA2405136C/en not_active Expired - Lifetime
- 2001-04-02 EP EP01926512A patent/EP1268405B1/de not_active Expired - Lifetime
- 2001-04-02 EP EP05025970A patent/EP1650188A1/de not_active Withdrawn
- 2001-04-02 US US09/824,111 patent/US6387950B2/en not_active Expired - Fee Related
- 2001-04-02 ES ES01926512T patent/ES2267754T3/es not_active Expired - Lifetime
- 2001-04-02 DE DE60121145T patent/DE60121145T2/de not_active Expired - Lifetime
- 2001-04-02 JP JP2001572454A patent/JP2003534246A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20010039293A1 (en) | 2001-11-08 |
| DE60121145T2 (de) | 2007-05-31 |
| EP1650188A1 (de) | 2006-04-26 |
| AU2001253045A1 (en) | 2001-10-15 |
| WO2001074759A1 (en) | 2001-10-11 |
| CA2405136A1 (en) | 2001-10-11 |
| JP2003534246A (ja) | 2003-11-18 |
| TWI281911B (en) | 2007-06-01 |
| US6387950B2 (en) | 2002-05-14 |
| ATE331703T1 (de) | 2006-07-15 |
| EP1268405A1 (de) | 2003-01-02 |
| CA2405136C (en) | 2009-06-16 |
| ES2267754T3 (es) | 2007-03-16 |
| EP1268405B1 (de) | 2006-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60121145D1 (de) | Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln | |
| NO932983D0 (no) | Fettsyrebehandling | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| DE60016393D1 (de) | Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe | |
| DE69523350T2 (de) | Behandlung von hyperproliferativen Gefässerkrankungen | |
| CY1111951T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
| DE69623899T2 (de) | Behandlung von Tinnitus mit neuroprotektiven Wirkstoffen | |
| DK0694545T3 (da) | Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder | |
| KR880009948A (ko) | 항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체 | |
| FI923663A0 (fi) | Terapeutiska foereningar. | |
| DE69327328D1 (de) | Verwendund von norastemizol zur behandlung der allergischen rhinitis | |
| FI923664A (fi) | Piperidinderivat | |
| KR900016135A (ko) | 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체 | |
| NO20014240D0 (no) | C16-umettede FP-selektive prostaglandinanaloger | |
| CY1111900T1 (el) | Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda) | |
| NO923198L (no) | Terapeutiske midler | |
| BR9906975A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero | |
| TR200102009T2 (tr) | Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı | |
| ES2049703T3 (es) | Derivados sulfurados de acidos biliares. | |
| MXPA02005088A (es) | Tratamiento de trastornos del ritmo cardiaco con n6-substituida-5'(n-substituida) carboxamidoadenosinas. | |
| ES2073871T3 (es) | Tiazolidin-2,4-dionas en el tratamiento de la hipertension. | |
| DE69910706D1 (de) | Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie | |
| RU96113185A (ru) | Раствор для лечения заболеваний и повреждений роговицы "кератан-с" | |
| EE04951B1 (et) | R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine unehirete raviks | |
| IT1245631B (it) | Impiego di composti macrolidi come agenti anti-infiammatori per il trattamento di malattie provocate da cessione di istamina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |